Treatment Resistant Schizophrenia Based on the DTMS
Conditions
Keywords
Deep Transcranial Magnetic Stimulation, Treatment Resistant Schizophrenia, H1 coil
Brief summary
Negative symptoms and cognitive dysfunction are of importance for the prognosis of the patients of schizophrenia. Based on the hypothesis that deep transcranial magnetic stimulation(dTMS) on prefrontal cortex #PFC# could down-regulate the glutamate level of PFC and regulate the functional network in patients with treatment resistance schizophrenia,this research plan to utilise multimodal functional magnetic imaging method(including structural MRI,resting-state functional magnetic resonance imaging and 1H-MRS) to investigate therapeutic efficacy of high-frequency deep transcranial magnetic stimulation on SZ patients symptoms,as well as to elucidate the correlation between treatment effects and glutamate level of PFC
Detailed description
This study includes 87 treatment resistance schizophrenia patients. This study will investigate 1)abnormalities of the glutamate level of PFC in patients with schizophrenia compared to healthy controls by using 1H-MRS technique. 2)potential modulation effects of deep transcranial magnetic stimulation(dTMS) on prefrontal cortex function of patients with schizophrenia. 3)the therapeutic efficacy of dTMS on cognitive impairments and other psychotic symptoms of patients with schizophrenia by adopting cognitive function and psychotic symptoms evaluation,as well as to explore the optimal dTMS treatment pattern on cognitive function.
Interventions
DEVICEdeep transcranial magnetic stimulation with H1 coil
Sham deep transcranial magnetic stimulation on PFC .Duration:40 days.
DEVICEHigh frequency deep transcranial magnetic stimulation with H1 coil
high frequency(20Hz) deep transcranial magnetic stimulation on PFC .Duration:40 days.
DEVICEiTBS deep transcranial magnetic stimulation with H1 coil
iTBS deep transcranial magnetic stimulation on PFC .Duration:40 days.
Sponsors
Shanghai Mental Health Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Patients with schizophrenia who meet the dsm-5 diagnostic criteria * Aged from 18 to 55 * Right-handedness, normal hearing, visual acuity or corrected visual acuity * Written informed consent of the patient and his/her family * All patients received MINI 7.0 structured interviews
Exclusion criteria
* Patients who are currently taking clozapine or who have failed to respond to a full course of treatment with clozapine * Current or past neurological illness,severe physical illness,substance abuse or addiction,alcohol dependence,mental retardation,pregnancy or lactation,extreme agitation, stupor, negative suicide,or those who can not cooperate * Medically unstable for at least 1 month
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in Positive and Negative Syndrome Scale(PANSS) | baseline,24 hours after the dTMS treatment,40 days | Change from baseline in Positive and Negative Syndrome Scale(PANSS) after dtms treat 40 days |
| Change from baseline in MATRICS Consensus Cognitive Battery | baseline,24 hours after the rTMS treatment,40 days | MATRICS Consensus Cognitive Battery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of PFC neurogenesis | baseline,24 hours after the dTMS treatment,40days | Quantify neural stem cells in hippocampal by using H1-MRS |
Countries
China
Contacts
Primary ContactDengtang Liu, M.D.
Outcome results
None listed